These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21570197)

  • 1. Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells.
    Chen S; Li X; Feng J; Chang Y; Wang Z; Wen A
    Med Hypotheses; 2011 Aug; 77(2):206-8. PubMed ID: 21570197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL; Xia W; Spector NL
    Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
    Azuma K; Tsurutani J; Sakai K; Kaneda H; Fujisaka Y; Takeda M; Watatani M; Arao T; Satoh T; Okamoto I; Kurata T; Nishio K; Nakagawa K
    Biochem Biophys Res Commun; 2011 Apr; 407(1):219-24. PubMed ID: 21377448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.
    Chen S; Zhu X; Qiao H; Ye M; Lai X; Yu S; Ding L; Wen A; Zhang J
    Tumour Biol; 2016 Feb; 37(2):2321-31. PubMed ID: 26369543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
    Burris HA; Hurwitz HI; Dees EC; Dowlati A; Blackwell KL; O'Neil B; Marcom PK; Ellis MJ; Overmoyer B; Jones SF; Harris JL; Smith DA; Koch KM; Stead A; Mangum S; Spector NL
    J Clin Oncol; 2005 Aug; 23(23):5305-13. PubMed ID: 15955900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
    Zhu X; Wu L; Qiao H; Han T; Chen S; Liu X; Jiang R; Wei Y; Feng D; Zhang Y; Ma Y; Zhang S; Zhang J
    J Cell Biochem; 2013 Dec; 114(12):2643-53. PubMed ID: 23794518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of HER-targeted therapy with lapatinib in breast cancer.
    McArthur H
    Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of lapatinib resistance in HER2-driven breast cancer.
    D'Amato V; Raimondo L; Formisano L; Giuliano M; De Placido S; Rosa R; Bianco R
    Cancer Treat Rev; 2015 Dec; 41(10):877-83. PubMed ID: 26276735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Chu I; Blackwell K; Chen S; Slingerland J
    Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib and breast cancer: current indications and outlook for the future.
    Moreira C; Kaklamani V
    Expert Rev Anticancer Ther; 2010 Aug; 10(8):1171-82. PubMed ID: 20735304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.
    Fabi A; Merola R; Ferretti G; Di Benedetto A; Antoniani B; Ercolani C; Nisticò C; Papaldo P; Ciccarese M; Sperduti I; Vici P; Marino M; Gori S; Botti C; Malaguti P; Cognetti F; Mottolese M
    Expert Opin Pharmacother; 2013 Apr; 14(6):699-706. PubMed ID: 23472669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
    Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
    Qi L; Zhang B; Zhang S; Ci X; Wu Q; Ma G; Luo A; Fu L; King JL; Nahta R; Dong JT
    Oncotarget; 2017 May; 8(22):36054-36066. PubMed ID: 28415602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.
    Decensi A; Puntoni M; Pruneri G; Guerrieri-Gonzaga A; Lazzeroni M; Serrano D; Macis D; Johansson H; Pala O; Luini A; Veronesi P; Galimberti V; Dotti MC; Viale G; Bonanni B
    Cancer Prev Res (Phila); 2011 Aug; 4(8):1181-9. PubMed ID: 21685235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib-associated toxicity and practical management recommendations.
    Moy B; Goss PE
    Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib for breast cancer: a review of the current literature.
    MacFarlane RJ; Gelmon KA
    Expert Opin Drug Saf; 2011 Jan; 10(1):109-21. PubMed ID: 21091041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.
    Xia W; Bacus S; Hegde P; Husain I; Strum J; Liu L; Paulazzo G; Lyass L; Trusk P; Hill J; Harris J; Spector NL
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7795-800. PubMed ID: 16682622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.